Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 6Carcinoma, Renal Cell 5Brain Neoplasms 3Neoplasm Metastasis 2Multiple Myeloma 2Melanoma 2Kidney Neoplasms 2Glioma 2Glioblastoma 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Thyroid cancer, medullary 1Thyroid Neoplasms 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Thrombocytosis 1Skin Neoplasms 1Salivary Gland Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Osteosarcoma 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Gemcitabine 8Capecitabine 6pembrolizumab 5Carboplatin 5Pemetrexed 3Paclitaxel 3Oxaliplatin 3Irinotecan 3regorafenib 2osimertinib 2Taxes 2Sunitinib 2Radiotherapy 2Fluorouracil 2Cisplatin 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1tislelizumab 1tegafur-gimeracil-oteracil 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1sintilimab 1seribantumab 1selinexor 1ruxolitinib 1rubitecan 1pralsetinib 1palbociclib 1olaparib 1niraparib 1linifanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma × cabozantinib × Clear all
NCT04230954 2022-06-07

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

University of South Alabama

Phase 2 Terminated
5 enrolled
Gynecologic

Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡